Keenova Therapeutics plc 8-K

What Happened

• On May 12, 2026, Keenova Therapeutics plc announced and filed an 8-K reporting its financial results for the three months ended March 31, 2026. The company also furnished supplemental unaudited pro forma financial results for the three months ended March 28, 2025. The details of the results are provided in Exhibit 99.1 (Q1 financial results) and Exhibit 99.2 (supplemental pro forma information). The filing was signed by Christiana Stamoulis, President and Chief Financial Officer.

Key Details

• Filing date: May 12, 2026 (Form 8-K, Item 2.02 and Item 9.01).
• Reported period: three months ended March 31, 2026 (primary results in Exhibit 99.1).
• Comparative pro forma period: three months ended March 28, 2025 (supplemental unaudited pro forma in Exhibit 99.2).
• Authorized signatory: Christiana Stamoulis, President & CFO.

Why It Matters

• Quarterly results provide investors with updated information on Keenova’s earnings, revenue, cash position and overall financial condition for Q1 2026; the pro forma information helps compare performance across periods on a consistent basis. Retail investors should review Exhibits 99.1 and 99.2 to see the specific revenue, profit/loss and cash metrics disclosed, and to assess trends that could affect near-term valuation and financing needs.